Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Verploegen

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Plos Biology|January 7, 2016
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell SurfaceRob N de Jong, Frank J Beurskens, Sandra Verploegen, et al.
Ebiomedicine|January 26, 2020
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosingPatrick J Engelberts, Ida H Hiemstra, Bart de Jong, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2013
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchangeAran F Labrijn, Joyce I Meesters, Bart E C G de Goeij, et al.
Nature Biotechnology|July 25, 2022
Logic-gated antibody pairs that selectively act on cells co-expressing two antigensSimone C Oostindie, Derek A Rinaldi, Gijs G Zom, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Plos Biology|January 7, 2016
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell SurfaceRob N de Jong, Frank J Beurskens, Sandra Verploegen, et al.
Ebiomedicine|January 26, 2020
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosingPatrick J Engelberts, Ida H Hiemstra, Bart de Jong, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2013
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchangeAran F Labrijn, Joyce I Meesters, Bart E C G de Goeij, et al.
Nature Biotechnology|July 25, 2022
Logic-gated antibody pairs that selectively act on cells co-expressing two antigensSimone C Oostindie, Derek A Rinaldi, Gijs G Zom, et al.
Pageof 2